Drug Database
Back to search

Japan· JP-2149012F2020

インダパミド

A indapamide product containing インダパミド, registered in Japan by 京都薬品工業, on the national reimbursement list. The same ATC class is registered in 16 of our 19 countries.

On Japan’s NHI price listATC C03BA11

Checked against MHLW / PMDA (Japan) on

Informational only — not a medical device.

SOURCE REGISTER · JPMHLW / PMDA (Japan)normalisedインダパミドATCC03BA11REGISTER NO.JP-2149012F2020PACKS LISTED0CHECKEDSeptember 25, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about インダパミドAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Indapamide is registered in 16 of 19 countries.

Countries holding a registration under ATC C03BA11 (indapamide), each read from that country’s own register.

  • This record: Japan, from MHLW / PMDA (Japan)
  • 9 of them publish a price we can compare per daily dose
Search indapamide products by name

Indapamide · ATC C03BA11

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of indapamide costs, country by country.

Normalised to the WHO defined daily dose (2.5 mg), the median price runs from $0.16 in Spain to $0.58 in Switzerland — a ×3.7 gap.

  • 4 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Indapamide · price per daily dose (2.5 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$0.58
  • FR France$0.26
  • IT Italy$0.17
  • ES Spain$0.16
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

MHLW / PMDA (Japan)
Active substance
インダパミド
Manufacturer
京都薬品工業
Country
Japan (JP)
ATC code
C03BA11
ATC class
Indapamide
Defined daily dose
2.5 mg, O
Reimbursed
Yes
Source register
MHLW / PMDA (Japan)
Last checked
September 25, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

347 interactions on record for indapamide.

Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check indapamide against other medicinesHow interaction checks work

Indapamide · interactions on record

347 records

  • 4 severe
  • 208 moderate
  • 18 minor
  • 69 info

Most severe, free to view

  • CisaprideA03FA02severe
  • DolasetronA04AA04severe
  • Aminolevulinic acidL01XD04severe
  • Arsenic trioxideL01XX27severe

48 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same class

Other records under C03BA11

Indapamide, as other registers publish it.

All indapamide products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ec279845-b8b2-4850-a104-8aa5ed874123
GET /v1/drugs/ec279845-b8b2-4850-a104-8aa5ed874123?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "spec": "２ｍｇ１錠",
  "marks": "局",
  "source": "mhlw",
  "remarks": null,
  "yj_code": "2149012F2020",
  "category": "内用薬",
  "price_yen": 11.7,
  "generic_name": "インダパミド",
  "product_name_jp": null,
  "therapeutic_class": "2149",
  "transitional_expiry": null
}
API referenceMCP serverPlans

See everything about indapamide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console